VEGFB and metabolic syndrome: Our findings are identical with the evidence that inhibition of VEGF-B signaling pathways or decreased expression of VEGF-B relieves excess fatty accumulation in the liver, and normalizes glucose levels, and ameliorates dyslipidemia (Hagberg et al., 2012[14]).